Keyword: Tango Therapeutics
The agreement gives Gilead the option to pick up the worldwide rights to five targets discovered and validated by Tango.
Atara hires ex-Genentech SVP to lead R&D, Semma names former Novartis CAR-T developer as CEO, and GSK's CFO heads for the exit.
AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.
Allergan CFO Hilado and Gilead COO Young will retire from their positions and Rubius has poached a GSK SVP as CMO.